Beimei Pharma Files IPO Prospectus: A Decade of Focus on Transdermal Drug Delivery with an Innovation-Driven Industrialization Platform

The history of cutaneous drug administration can be traced back to primitive societies, when early humans learned through practice to use natural materials such as clay and leaves to accelerate the healing of traumatic injuries. The earliest Chinese record of topical medicinal patches appears in the Moxibustion Classic on Silk Manuscripts (Boshu Jiujing) from the 3rd century BCE, which documents the use of mustard plaster applied to the Baihui acupoint for treating venomous snakebites. These ancient insights collectively constitute the precursor to modern transdermal drug delivery systems (TDDS).

Transdermal Drug Delivery (TDD) is a drug administration system that delivers medications through the skin. It provides sustained and controlled drug release, facilitates discontinuation of therapy, is suitable for self-administration, and avoids the hepatic first-pass effect and gastrointestinal adverse reactions.

“Transdermal drug delivery is a safe and practical method of drug administration, particularly for patients with chronic diseases who require long-term treatment and stable drug levels. This technology holds immense application potential and represents a field ripe with opportunities, worthy of in-depth exploration and innovation,” said Dr. Ju Lun, founder of Beijing Beimei Pharmaceutical Co., Ltd.

Driven by a passion for exploration and innovation in the industry, Dr. Ju Lun and Dr. Li Feifei founded Beijing Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as “Beimei Pharmaceutical”) in 2022. As an industry-leading provider and partner offering full-chain services for transdermal drug delivery, Beimei Pharmaceutical possesses comprehensive capabilities spanning active pharmaceutical ingredients (APIs), core excipients, production equipment, manufacturing facilities, and commercialization. The company provides clients with one-stop industrialization solutions for complex formulations, including local and systemic transdermal drug delivery systems.

From the perspective of the market landscape for transdermal drug delivery, globally approximatelyYesThirty drugs have been successfully developed into transdermal formulations and approved for market launch. Among these products,China has a relatively limited variety of transdermal formulations, with significant room for improvement in technological R&D and product diversification.

In light of the relatively late start of China's transdermal drug delivery industry,Dr. Ju Lun stated, “The design of transdermal drug delivery systems is a complex process that requires comprehensive consideration of the compatibility between the drug and excipients, skin permeability, the intrinsic properties of the drug itself, and the administration needs of the target patient population. The successful development and industrialization of transdermal drug delivery require a deeper understanding of the biological interactions between drugs and the skin, as well as the physical and chemical mechanisms of various polymeric materials. This is particularly true forRegarding novel transdermal drug delivery systems, China started relatively late, and its industrial chain—from key excipients to core equipment—heavily relies on imports.”

“To rapidly address the industry’s shortcomings,The Beimei team has made positive contributions to the development and registration of key excipients, as well as equipment modification.Leveraging profound understanding and translational experience in transdermal drug delivery, from technology to industrialization,Beimei Team“Since its inception, the company has regarded the closed-loop integration of drug R&D, industrialization, and commercialization as the primary driver of its business development. Accordingly, it has established a comprehensive industrialization platform that covers all stages—from active pharmaceutical ingredients (APIs), key excipients, production and specialized quality control equipment, and manufacturing bases to commercialization—thereby reducing reliance on imported technologies and achieving sustainable development,” said Dr. Ju Lun.

Furthermore, the development of transdermal drug delivery involves multiple disciplines, including dermatopharmacokinetics, pharmacology, materials science, physical chemistry, polymer chemistry, and pharmaceutics. It is a multidisciplinary cross-disciplinary research endeavor, requiring a cross-functional, composite team for both drug formulation development and commercialization.

Under the leadership of its two founders, Beijing Beimei Pharmaceutical Co., Ltd. has built an experienced, multidisciplinary team.Among them, Dr. Li Feifei and Dr. Ju Lun are both industry “veterans” with pharmaceutical backgrounds and extensive experience in translational medicine. Dr. Li holds a Ph.D. in Pharmaceutics from Shenyang Pharmaceutical University, previously worked at leading pharmaceutical companies, and has accumulated 18 years of experience in drug development, regulatory submissions, and industrialization. Dr. Ju completed his postdoctoral research at the School of Pharmaceutical Sciences, Peking University, serves as an Executive Director of the Peking University Young CEO Club, and has held positions at several large multinational pharmaceutical companies.

The backgrounds of the remaining core team members span multiple disciplines, including clinical medicine, industrial pharmaceutics, computational chemistry, and materials science. This high-caliber interdisciplinary talent pool provides robust human resource support for the company in addressing complex technical challenges during the research and development of transdermal drug delivery technologies.

Through the joint efforts of its core team, Beijing Beimei Pharmaceutical Co., Ltd. has leveraged its foundational expertise in chemistry, molecular design, materials science, and pharmaceutical formulations to continuously strengthen its capabilities in the design, development, and quality enhancement of key excipients. The company has established multiple key technologies for transdermal drug delivery systems, encompassing drug loading, solubilization, controlled release, improvement of patch mechanical properties, and pressure-sensitive adhesive molding processes, thereby providing solutions for more effective drug delivery.

After achieving breakthroughs in key technologies, the second challenge the team needs to address is how to accelerate the R&D process and expedite the commercialization of technological products.In response, Beijing Beimei Pharmaceutical Co., Ltd. has built a BGi design platform with independent intellectual property rights, leveraging its solid multidisciplinary technical barriers and R&D capabilities.

“BGi is an intelligent drug design platform built upon physicochemistry, medicinal chemistry, materials science, and computational chemistry. By elucidating the relationships between transdermal system compatibility, thermodynamic properties, and permeation rates, as well as the correlations between polymer matrix structures, biocompatibility at the administration site, and release rates, the platform enables efficient formulation and process design for improved new drugs, along with predictions of their safety and efficacy. Current data indicate that BGi can enhance R&D efficiency by at least 30%,” introduced Dr. Ju Lun.

Supported by its foundational knowledge architecture and technological platforms, Beijing Beimei Pharmaceutical Co., Ltd. has expanded its R&D scope beyond individual drugs or specific indications. Leveraging the advantages of its universal platform, the company has made a strong entry into the development of long-acting formulations for chronic disease management, particularly in the areas of anti-inflammatory and analgesic medications.

Dr. Ju Lun emphasized, “Each product has its unique characteristics, and pharmaceuticals strictly adhere to three core elements: safety, efficacy, and quality controllability. Currently, our drug review policies are becoming increasingly scientific. Among these, topical products are generally categorized into two major classes based on their mechanism of action: one class achieves systemic effects through local administration, while the other exerts local effects through local administration. The lidocaine hydrochloride gel approved under the leadership of the Beijing Beimei Pharmaceutical team belongs to the latter category.”

Lidocaine Hydrochloride Gel is a product that primarily provides lubrication and analgesia.Topical Anesthetic Lubricant, with an onset of action as rapid as 5 minutes, and the product has a wide range of clinical applications, being suitable for use in more than ten departments including anesthesiology, urology, gastroenterology, and obstetrics and gynecology.

More importantly, this product, spearheaded by the core team at Beijing Beimei Pharmaceutical Co., Ltd. for regulatory approval, is included in the National Reimbursement Drug List and represents the first approved generic of its kind to have successfully obtained a clinical trial waiver.

Dr. Ju Lun explained,“After our team submitted the application for a clinical trial waiver for this drug, the U.S. FDA also released its submission guidelines for this product. Unaware of the FDA’s announcement at the time, we found that our clinical waiver submission package to the CDE was fully aligned with the guidelines subsequently published by the FDA.”This not only demonstrates the team members’ keen insight into industry trends and regulatory requirements, but also affirms Beijing Beimei Pharmaceutical Co., Ltd.’s mature capability in commercialization and translation.

In recent years, transdermal formulation technology has witnessed significant advancements. According to Research and Markets, the global transdermal drug delivery market is projected to reach USD 10.67 billion by 2026. Meanwhile, the Chinese market is also demonstrating strong growth momentum, with its market size approaching RMB 20 billion.

Facing a rapidly expanding market worth tens of billions, Beijing Beimei Pharmaceutical Co., Ltd., as an industry-leading provider and partner for the full industrial chain of transdermal drug delivery services, is committed to building cost advantages for its products after resolving technical and efficiency challenges.

First, the company controls basic manufacturing costs by co-establishing production lines with partners. Second, from the perspective of technological innovation, the company collaborates with medical equipment manufacturers to improve and optimize equipment while enhancing process capabilities, thereby achieving efficient large-scale production and further reducing production costs. Finally, taking improved new drugs as an example, Beijing Beimei Pharmaceutical Co., Ltd. conducts comprehensive assessments at the initial project stage and leverages its proprietary technology platform to ultimately select dosage forms with clinical advantages and higher clinical benefits.

Supported by its comprehensive advantages, Beijing Beimei Pharmaceutical Co., Ltd. not only continues to overcome key technical constraints hindering the development of transdermal formulations but also accelerates the commercialization of its pipeline through the construction of a full industry chain, leveraging faster and more cost-effective industrialization capabilities.

At the conclusion of the interview, Dr. Ju Lun stated, “Drug development is characterized by long cycles and high risks, necessitating collaboration among multiple parties with complementary strengths. Beimei will forge deep partnerships with its collaborators, engaging in comprehensive strategic cooperation across project initiation, R&D, manufacturing, cost control, and sales, with the aim of shortening drug time-to-market, improving conversion rates, and enhancing return on investment.”

“In the future, Beijing Beimei Pharmaceutical Co., Ltd. will focus on its core business, pursue continuous innovation, steadily enhance its R&D capabilities, and accelerate the development of its existing product pipeline. In terms of long-term planning, the company will further improve its functional excipient technology platform and BGi technology platform, while gradually promoting the commercialization and sales of its product pipeline to meet patients’ clinical needs. This will ensure the company’s sustainable development, attract like-minded partners and investors, and ultimately enable it to grow into an industry leader with continuous innovation and effective translation as its core competencies.”

Since its inception in 2023, the Transdermal Technology Innovation Alliance (TTIA) has been delivering global intelligence and networking resources covering the entire industry chain and full lifecycle of transdermal drug delivery systems to professionals in China’s transdermal sector. Through online live broadcasts, offline salons, resource matchmaking events, and international study tours, TTIA helps industry practitioners avoid common pitfalls, anticipate future competitive landscapes, accelerate R&D progress, secure sales channels in advance, and capture emerging business opportunities.

The China Transdermal Drug Delivery Alliance (TTIA) will also provide in-depth, full-lifecycle services for transdermal formulations, covering investment, project initiation, R&D, marketing authorization holding, manufacturing, supply chain localization, sales, and product transfer.

For more information about the Transdermal Technology Innovation Alliance, please feel free to contact us: